ClinicalTrials.gg
Not yet recruitingNCT06263816CARVECIRUpdated Jun 4, 2025

Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

A Phase 3 interventional study of Experimental group: Patients will be treated with carvedilol. and Control group: Patients will receive a placebo. in Asymptomatic Cirrhosis and Clinically Significant Portal Hypertension, sponsored by University Hospital, Tours. Not yet recruiting at 24 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by University Hospital, Tours · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Death with a site in France — 14 open to participants now, 15 under way, 3 of them phase 3. Death · France.

Planned enrollment
6th of 13
290 · median 242
Started
2025
with 2 others
Phase 3
6 of 51
2 open now
Primary completion
2027-07
later than 8 of 14 live
Registered
39th of 51
by date

Among the 51 studies in Death with a site in France, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 39th registered.

Death

457 studies on the registry are indexed under Death; 85 are open to participants now.

Browse Death studies →

Open to participants now

14 of the 51 studies in Death with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Death with a site in France, or all of them as a file.
02

Study summary

Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.

The usefulness of carvedilol to prevent decompensation of cirrhosis in patients with TE-LSM ≥ 25 kPa as a surrogate marker for clinically significant portal hypertension, has never been evaluated in a clinical trial.

Read the detailed description

Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.

Portal hypertension (PH) is the strongest predictor of decompensation. Hepatic venous pressure gradient (HVPG) is the reference standard for the evaluation of PH. HVPG ≥10 mm Hg, called "clinically significant portal hypertension", identifies a population with a high risk of decompensation. HVPG measurement is an invasive procedure, only routinely available in expert centers. Liver stiffness measurement (LSM) using transient elastography (TE) (referred as TE LSM) using Fibroscan can provide an indirect estimate of HVPG. TE-LSM ≥ 25 kPa can rule-in HVPG ≥10 mm Hg with a specificity >90%.

Nonselective beta-blockers (NSBBs) lower portal pressure by decreasing portal venous inflow. Carvedilol also decreases intrahepatic vascular resistance, and thereby achieves a greater reduction in portal pressure than propranolol. At low-dose (≤12.5 mg/day), carvedilol is safe in patients with compensated cirrhosis.

In patients with asymptomatic cirrhosis, NSBBs were recommended when medium or large varices (high-risk varices) are present for prophylaxis of variceal bleeding. In a recent randomized controlled trial, the PREDESCI study (NCT01059396), NSBBs reduced incidence of decompensation or death in patients with compensated cirrhosis with clinically significant portal hypertension. In the PREDESCI study, the diagnosis of clinically significant portal hypertension was based on invasive HVPG measurement, so that its results are not applicable in clinical practice.

The usefulness of carvedilol to prevent decompensation of cirrhosis in patients with TE-LSM ≥25 kPa as a surrogate marker for clinically significant portal hypertension, has never been evaluated in a randomized controlled trial.

03

Conditions studied

  • Asymptomatic Cirrhosis
  • Clinically Significant Portal Hypertension

Browse trials for

Keywords

  • carvedilol
  • decompensation
  • death
  • asymptomatic cirrhosis
  • significant portal hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female≥ 18 years of age
  • Cirrhosis related to or virus without viral replication for at least 2 years.

Or Cirrhosis related to alcohol consumption (active or abstinent) Or Cirrhosis related to metabolic syndrome or cryptogenic with \< 30 kg/m2

  • 2 TE-LSM (Fibroscan®) performed in fasting conditions, using either the M or the XL probe >=25 kPa, within 12 months before inclusion
  • Absence of medium or large varices or small varices with red signs at endoscopy within 3 months before inclusion
  • A5 to B8
  • Affiliation to a French social security system.
  • Written obtained from the participant or participant's legal representative
  • For child-bearing aged women, using oral contraceptive, or intrauterine device or mechanical contraception

Exclusion criteria

Exclusion Criteria:

  • History of overt ascites or encephalopathy \<12 months before inclusion
  • Treatment with either diuretics or lactulose or rifaximin \<3 months before inclusion
  • Any history of portal hypertension related bleeding
  • Baseline heart rate \<65/min or systolic blood pressure \<100 mm Hg
  • Previous transjugular intrahepatic portosystemic shunt (TIPSS) or liver transplantation
  • Previous history or active hepatocellular carcinoma
  • (CKD-Epi) \< 30 mL/min
  • Strict indication to selective or nonselective beta-blockers: history of acute myocardial infarction, congestive heart failure
  • Strict to selective or nonselective beta-blockers:

    • decompensated congestive heart failure
    • grade 2 or 3 atrioventricular block
    • sinus node dysfunction without pacemaker
    • severe asthma according to WHO classification [63]
    • severe , defined stage 3 or 4 of the GOLD classification, i.e.\<50% of the predicted value (https://goldcopd.org/)
    • severe Raynaud disease, defined as repetitive episodes of biphasic colour (at least two) of pallor, cyanosis, erythema, in addition to paresthesia or numbness, occurring in both cold and normal environments [64].
  • Known to carvedilol
  • Concomitant use of Cimétidin
  • Concomitant use of class I antiarythmic agents (except lidocaïn) (i.e.cibenzoline, disopyramide, flécaïnide, hydroquinidine méxilétine, propafenone, quinidine)
  • Concomitant use of calcium antagonists: diltiazem, vérapamil and bépridil
  • Concomitant use of clonidine, méthyldopa, guanfacine, moxonidine, rilménidine
  • Concomitant use of fingolimod
  • Concomitant use of potent inhibitors (e.g. ketoconazole, protease inhibitors) or inductors (e.g. rifampin, carbamazepine, phenytoin) of (see appendix 7)
  • Pregnancy or breastfeeding
  • Non ability for participant to comply with the requirements of the study
  • \<12 months
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    Carvédilol

    Drug: Experimental group: Patients will be treated with carvedilol.

  • Placebo comparator
    Placebo

    Other: Control group: Patients will receive a placebo.

Interventions

  • DrugExperimental group: Patients will be treated with carvedilol.

    Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.

  • OtherControl group: Patients will receive a placebo.

    Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of low dose carvedilol (<=12.5 mg per day) versus placebo on the occurrence of decompensation of cirrhosis or liver-related death at 36 months

    Primary endpoint will be the occurrence, within 36 months after inclusion, of either decompensation of cirrhosis or liver-related death. Decompensation of cirrhosis is defined as a composite endpoint including one event among: overt ascites, overt hepatic encephalopathy and variceal bleeding according to Baveno VII consensus conference \[1\]. Liver-related death is defined as death occurring in the context of complicated ascites (e.g. spontaneous bacterial peritonitis or acute kidney injury), encephalopathy, variceal hemorrhage, or ACLF

    Time frame: 36 months

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jul 2027, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 16, 2024
StartEst.
Jun 17, 2025
Primary completionEst.
Jul 17, 2027
CompletionEst.
Jul 17, 2030
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06263816
Collaborators
Centre Hospitalier Universitaire Amiens Picardie, Centre Hospitalier Universitaire Angers, Assistance Publique Hopitaux Paris BEAUJON, Centre Hospitalier Universitaire Caen, Centre Hospitalier intercommunal de Créteil, Hospices Civils de Lyon, Centre Hospitalier Universitaire Grenoble, Centre Hospitalier Universitaire Haut Lévêque, Centre Hospitalier Régional Universitaire Lille, Centre Hospitalier Universitaire Jean Minjoz, Assistance Publique Hopitaux Paris AVICENNE, Centre Hospitalier Universitaire Clermont Ferrand, Assistance Publique Hopitaux Paris LA PITIE SALPETRIERE, Centre Hospitalier Universitaire Pontchaillou, Assistance Publique Hopitaux Paris ST ANTOINE, Assistance Publique Hopitaux Paris PAUL BROUSSE, University Hospital, Montpellier, Assistance Publique Hopitaux Paris HENRI MONDOR, Centre Hospitaliser Départemental de Vendée, Nantes University Hospital, Centre Hospitalier Universitaire Dijon, CHU de Reims, Hôpitaux Universitaires de Strasbourg, University Hospital, Toulouse
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jun 17, 2025 (estimated)
Primary completion
Jul 17, 2027 (estimated)
Completion
Jul 17, 2030 (estimated)
Last update
Jun 4, 2025

Study contacts

Laure ELKRIEF, MD-PhD
Contact
l.elkrief@chu-tours.fr
+33 247475965
Laure ELKRIEF, MD-PhD
study director · University Hospital, Tours

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion